Abstract: The invention relates to compounds of formula (I): wherein R1, R2, R3, R4, R5 and are as defined in the description.

Abstract: The invention relates to a method of treating cirrhosis which comprises administering to a subject in need thereof lanifibranor or a deuterated derivative thereof.

Abstract: The invention relates to compounds of formula (I): wherein R1, R2, R3, R4, R5 and are as defined in the description.

Abstract: The invention relates to a method of treating cirrhosis which comprises administering to a subject in need thereof lanifibranor or a deuterated derivative thereof.

Abstract: The invention relates to compounds of formula: wherein R1 to R7 are as defined in the description. These compounds are useful as inhibitors of the YAP/TAZ-TEAD interaction.

Abstract: The invention relates to the use of a pan-PPAR agonist, or of a pharmaceutical composition containing said agonist, for the treatment of a fibrotic condition.

Abstract: The invention relates to the use of a pan-PPAR agonist, or of a pharmaceutical composition containing said agonist, for the treatment of a fibrotic condition.

Abstract: The present invention relates to the use of 4-methyl-2-oxo-2H-1-benzopyran-7-yl-5-thio-?-D-xylopyranoside in the treatment of a mucopolysaccharidosis such as type I mucopolysaccharidosis.

Abstract: The invention relates to the use of a pan-PPAR agonist, or of a pharmaceutical composition containing said agonist, for the treatment of a fibrotic condition.

Abstract: The invention relates to the use of a pan-PPAR agonist, or of a pharmaceutical composition containing said agonist, for the treatment of a fibrotic condition.

Abstract: The present invention relates to the use of 4-methyl-2-oxo-2H-1-benzopyran-7-yl-5-thio-?-D-xylopyranoside in the treatment of a mucopolysaccharidosis such as type I mucopolysaccharidosis.

Abstract: The present invention relates to a method of treatment of a mucopolysaccharidosis with 4-methyl-2-oxo-2H-1-benzopyran-7-yl-5-thio-?-D-xylopyranoside.

Abstract: The present invention generally relates to a novel therapeutical use of liver X receptor (LXR) agonsits. More specifically, the present invention relates to the use of LXR agonist for the preparation of a medicament useful for the treatment and/or the prevention of a disease associated with beta cells degeneration, such as diabetes, and a method for increasing ex vivo viability of pancreatic islet cells, comprising contacting said islet cells with a LXR agonist.

Abstract: A method of increasing the ex vivo viability of pancreatic islet cells comprising contacting the islet cells with a liver X receptor (LXR) agonist, particularly an LXRalpha agonist. Examples of especially useful LXR agonists include GW3965 and T0901317.

Abstract: The present invention relates to the combined use of a PPAR? agonist and metformin for decreasing serum triglycerides.

Abstract: Certain peptides which exhibit high selectivity for the kappa opioid receptor (KOR) versus the mu opioid receptor and little or no CYP3A4 inhibitory activity including tetrapeptides of four D-isomer amino acid residues having a C-terminus which is an N-oxide-substituted amide such, as H-D-Phe-D-Phe-D-Nle-D-Arg-NH-4-picolyl-N-oxide.

Abstract: The present invention generally relates to a novel therapeutical use of liver X receptor (LXR) agonsits. More specifically, the present invention relates to the use of LXR agonist for the preparation of a medicament useful for the treatment and/or the prevention of a disease associated with beta cells degeneration, such as diabetes, and a method for increasing ex vivo viability of pancreatic islet cells, comprising contacting said islet cells with a LXR agonist.

Abstract: The present invention relates to the use of a ppar? agonist to treat patients suffering from weight gain associated with a ppar? agonist treatment.

Abstract: The present invention relates to a novel pharmaceutical combination, containing an inhibitor of platelet aggregation and a fÊbrate, where the inhibitor of platelet aggregation is preferably either aspirin or clopidogreL Such a pharmaceutical combination of an inhibitor of platelet aggregation and a fÊbrate is expected to be useful in the treatment and/or prevention of myocardial infarction (heart attack), cardiac arrest, peripheral vascular disease (including symptomatic carotid artery disease), congestive heart failure, ischemic heart disease, angina pectoris (including unstable angina), sudden cardiac death, unstable angina, as well as cerebrovascular events such as cerebral infarction, cerebral thrombosis, cerebral ischemia and transient ischemic attack, disorders related to bypass operations (angioplasty), fitting of endovascular prostheses and restenosis, and inflammatory disorders, including arthritic conditions such as rheumatoid arthritis and osteoarthritis, as well as asthma or related airway or resp

Abstract: The present invention relates to anti-obesity pharmaceutical compositions comprising orlistat and metformin and to the use of combinations of metformin and orlistat to treat patients suffering from obesity.